From A as in "astaxanthin" to Z as in "zinc"… It seems, there's a supplement for everything. Everything but active tissue repair. Yes, a healthy diet, anti-inflammatory vitamins and related compounds may help you recover from everything, ranging from the inevitable daily wear and tear of our stressful lives to a debilitating injury, but no legally available supplement has actively promoted wound, bone and overall tissue healing. Until now…
BPC-157 is a naturally occurring anti-ulcer agent
Initially described in the early 1990 (Sikiric 1993), Pentadecapeptide BPC 157 has been identified as an endogenous antiulcer peptidergic agent – in other words: BPC-157 is small peptide (only 15 amino acids) that occurs naturally in our gastric juice, where its main function seems to be to kickstart and accelerate the renewal and repair of the constantly assaulted lining of our intestinal tract.
From a mechanistic point of view, BPC-157 works by promoting key growth factors and modulating the nitric oxide pathway – it is thus not the simply vascular endothelial growth factor (VEGF) analog it is often misrepresented as. Rather than acting like VEGF it will promote the complex physiological processes that occur during wound healing and tissue regeneration and repair - both inside and outside of the gastrointestinal tract, where VEGF and related growth factors as they are promoted by BPC-157 has been shown to …
promote the regeneration of the cells of the intestinal wall (intestinal health | Sikiric 2018)
trigger the repair and replacement of atherosclerotic endothelial cells (cardiovascular health | Sikiric 2018)
prevent and reverse lesions of the intestinal tract, liver, and even brain as they can occur in response to the (ab-)use of certain pain medications (general organ health | Drmic 2018) and the cardiovascular side effects of anti-psychotics (heart health | Strinic 2017)
heal (stress-induced) ulcers and fistulas as they are increasingly common due to our stressful (this refers to "stress" as general oxidative stress) lifestyles (GI health and beyond | Szabo 2017; Grgic 2016)
serve as a remedy for a plethora of central nervous system disorders that originate in the gut by (a) the local repair of the intestinal lining and (b) direct neuroprotective effects in the brain (brain & CNS health | Sikiric 2016)
No wonder Sikiric et al. decided to call the protein they discovered in the early 90s a "B.P.C.", i.e. a "Body Protecting Compound", a compound that has hitherto gathered significant attention only within the athletic community – and that despite the fact that its ability to battle muscular (Brcic 2009) or tendon injuries (cf. Krivic 2008) is one of the least important health benefits of BPC. For people with Crohn's disease, IBS and other intestinal pathologies, for example, BPC-157 could literally be a life-saver - for everyone else a potentially health-promoting health-insurance, which acts on signaling pathways that have been implicated in heart and vascular health (Wada 2017) and seem to play a role in the etiology of vascular dementia, Alzheimer's (Mateo 2007; Garcia 2014) and general organ health.
In all fairness it must be said, however, that VEGF and co share one important quality with better known growth factors like IGF1: in some unfortunate contexts, they entail the risk of stimulating growth where you don't want it. Indiscriminately injecting copious amounts of straight VEGF is thus not an option. Using BPC-157 to promote its natural production, on the other hand, is an option – an option with a plethora of potential health benefits (see illustration):
Despite the lack of corresponding RCTs, the complex health benefits that have been associated with BPC-157 directly or one or several of the growth factors that are released in response to its use clearly suggest that the often-heard recommendation to use BPC-157 for acute injury treatment does not take advantage of the full regenerative potential of this unique peptide. Figuratively speaking, BPC-157 has the potential to be way more than an airbag, of which you'd want that it remains in its casing waiting for the one moment to save your life. Used continuously it could act pretty much like an advanced driver assistant system that initiates an emergency stop and/or evades collusions and hence renders the use of an airbag redundant.
Dosing and administration
BPC-157 does not share two central limitations that complicate the use of other secretagogues for medical purposes: BPC-157 is orally bioavailable (Sikiric 2018) and effective even at relatively low concentrations. A 2009 study by Brcic et al. that was published in the Journal of Physiological Pharmacology, for example, found a profound acceleration of the healing process of crushed muscles and transected muscle and tendons in rodents that received as little as 10 µg of BPC-157 – an amount that translates to only 5.4 µg of BPC-157 per kg body mass in humans.
Brcic's study is not the only one in which scientists absorbed impressive tissue healing in response to the "oral" administration of BPC-157. The problem, however, is that each of these studies simulated the oral administration of the agent by injecting the peptide into the peritoneum (body cavity). Why's that a problem? Well, while it is unquestionably a more convenient and reliable alternative to regular means of oral drug administration, we cannot say for sure if the injection into the inter-peritoneal cavity affects the bioavailability and pharmacology of BPC-157 differently than washing it down with water and/or even food.
Why you should choose transdermal time-release patches
Here's where AgeForce unique patch technology comes in. Having been developed to transport much larger peptides across the skin barrier, the new AgeForce BPC-157 Patches will progressively release your daily dose of BPC-157 into the circulation. By placing the patch on or next to an injured muscle, tendon, or other damaged tissues, the patches also have a certain tissue-specificity that would otherwise be seen only with injectable peptides.
Patch application can be general or site specific: Depending on where you place the patch you can thus focus on either the systemic or the local effects of BPC-157. When placed directly on or close to an injury such as a torn hamstring, the injured tissue will benefit particularly from the regenerative capacity of the patch. If you place the patch on the upper arm, the shoulders or other common application areas where the skin is relatively thin and the patch's full 5mg of BCP-157 will predominantly pass into the bloodstream, BPC-157 will exert its organ-protective, pro-regenerative effects throughout your whole body.
If you plan on using the BCP-157 patch continuously, it is important to remember that it shares the same U-shaped dose-benefit ratio you may know from other growth factor releasing peptides. Accordingly, we cannot recommend mega-dosing BPC-157 by applying several patches at a time over longer time spans – not because there's proven evidence of harm, but rather because we don't have sufficient safety data, yet.
Moreover, being dosed at 5mg/patch our new BPC-157 Patch already contains a significantly higher amount of the potent tissue regenerator than you'd need to initiate the repair processes. In that, it is important to note that our unique time-release technology allows the BPC-157 level in your blood and tissue to remain decently stable over a 24h period thus reducing the risk of side effects due to acute overdosing while still optimizing all the physiological processes that critically depend on VEGF and related growth factors; from general organ and vascular health to muscle recovery and bone, tendon and ligament healing.
In other words, with our patch you will get the benefits of injectable BPC-157 without the hassle of having to inject it – all by applying a single small patch to your skin.
The Food and Drug Administration has not evaluated the statements on this resource education page. Natural ingredients mentioned are not intended to diagnose, treat, cure or prevent any disease. No nutrient claims are made. All content is shared as educational information and is not meant to be construed as medical advice, nor should any content be used to self-diagnose or treat any medical condition; the material on this page does not take the place of professional care provided by a physician. The information on this page is fully referenced from source material published from studies and clinical trials available online.
Brcic, L., et al. "Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing." J Physiol Pharmacol 60.Suppl 7 (2009): 191-196.
Drmic, Domagoj, et al. "Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME." World journal of gastroenterology 23.29 (2017): 5304.
Garcia, Karina de Oliveira, et al. "Therapeutic effects of the transplantation of VEGF overexpressing bone marrow mesenchymal stem cells in the hippocampus of murine model of Alzheimer’s disease." Frontiers in aging neuroscience 6 (2014): 30.
Grgic, Tihomir, et al. "Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula." European journal of pharmacology 780 (2016): 1-7.
Huang, Tonglie, et al. "Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro." Drug design, development and therapy 9 (2015): 2485.
Karukonda, Sree RK, et al. "The effects of drugs on wound healing–‐part II. Specific classes of drugs and their effect on healing wounds." International journal of dermatology 39.5 (2000): 321-333.
Mateo, I., et al. "Low serum VEGF levels are associated with Alzheimer's disease." Acta Neurologica Scandinavica 116.1 (2007): 56-58.
, Predrag, et al. "A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC." Journal of Physiology-Paris 87.5 (1993): 313-327.
Sikiric, Predrag, et al. "Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications." Current neuropharmacology 14.8 (2016): 857-865.
Sikiric, P., et al. "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing." Current pharmaceutical design(2018).
Strinic, Dean, et al. "BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats." Life sciences 186 (2017): 66-79.
Stupnisek, Mirjana, et al. "Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats treated with heparin, warfarin, L-NAME and L-arginine." PloS one 10.4 (2015): e0123454.
Szabo, Sandor, et al. "“Stress” is 80 Years Old: From Hans Selye Original Paper in 1936 to Recent Advances in GI Ulceration." Current pharmaceutical design 23.27 (2017): 4029-4041.
Wada, Hiromichi, et al. "Vascular Endothelial Growth Factor-C Levels and Cardiovascular and All-cause Mortality in Patients With Suspected Coronary Artery Disease: From the ANOX Study." (2017): A13751-A13751.